These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 15701766

  • 1. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 7. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 8. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D.
    Can J Cardiol; 2005 May 15; 21(7):569-75. PubMed ID: 15940354
    [Abstract] [Full Text] [Related]

  • 9. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H, Jones PG, Marso SP, O'Keefe JH.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):821-6. PubMed ID: 16139131
    [Abstract] [Full Text] [Related]

  • 11. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL, Craddock D, Edwards K.
    Pharmacotherapy; 2006 Sep 06; 26(9):1297-306. PubMed ID: 16945052
    [Abstract] [Full Text] [Related]

  • 12. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL, Taber DJ.
    Ann Pharmacother; 2008 Jan 06; 42(1):116-20. PubMed ID: 18094340
    [Abstract] [Full Text] [Related]

  • 13. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S, Arora RR.
    Am J Ther; 2010 Jan 06; 17(1):e11-23. PubMed ID: 20090429
    [Abstract] [Full Text] [Related]

  • 14. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 06; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 06; 4(2):62-73. PubMed ID: 12806587
    [Abstract] [Full Text] [Related]

  • 16. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 06; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 17. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, Goto D, Yamada S, Yokoshiki H, Takeshita A, Tsutsui H, JCARE-CARD Investigators.
    Hypertens Res; 2010 Mar 06; 33(3):197-202. PubMed ID: 19960016
    [Abstract] [Full Text] [Related]

  • 18. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep 06; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 19. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 06; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the efficacy of ARBs across the cardiovascular continuum.
    Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP.
    Curr Med Res Opin; 2010 May 06; 26(5):1203-18. PubMed ID: 20302552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.